Economic evaluation of sipuleucel-T immunotherapy in castration-resistant prostate cancer

Expert Review of Anticancer Therapy

Volumn 14, Issue 1, 2014, Pages 63-73

  Holko, Przemysław ^a   Kawalec, Paweł ^b  

^a Centrum HTA w Krakowie   (Poland)

^b JAGIELLONIAN UNIVERSITY   (Poland)

Author keywords

castration resistant prostate cancer; cost utility analysis; immunotherapy; prostate cancer; quality adjusted life year; sipuleucel T immunotherapy

Indexed keywords

APC 8015F; PLACEBO; SIPULEUCEL T; UNCLASSIFIED DRUG;

CANCER IMMUNOTHERAPY; CANCER MORTALITY; CASTRATION RESISTANT PROSTATE CANCER; CHILL; CONTROLLED CLINICAL TRIAL (TOPIC); COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; ECONOMIC EVALUATION; FEVER; FLU LIKE SYNDROME; HEADACHE; HEALTH CARE COST; HUMAN; HYPERHIDROSIS; HYPERTENSION; INGUINAL PAIN; MALE; MYALGIA; OVERALL SURVIVAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; REVIEW; SENSITIVITY ANALYSIS;

CANCER VACCINES; COST-BENEFIT ANALYSIS; DRUG COSTS; HUMANS; IMMUNOTHERAPY; MALE; PATIENT SELECTION; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; QUALITY-ADJUSTED LIFE YEARS; TISSUE EXTRACTS;

EID: 84893091990     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.2014.856270     Document Type: Review

References (38)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J. Clin. 60, 277-300 (2010
2. Catalona WJ, Smith DS. Cancer recurrence and survival rates after anatomic radical retropubic prostatectomy for prostate cancer: Intermediate-Term results. J. Urol. 160, 2428-2434 (1999
3. Eastham JA, Scardino PT. Radical prostatectomy for clinical stage T1 and T2 prostate cancer. In: Comprehensive Textbook of Genitourinary Oncology (2nd Edition). Vogelzang NJ, Scardino PT, Shipley WU, Debruyne FM, Linehan WM (Eds). Lipincott Williams & Wilkins, Philadelphia, PA, USA, 722-738 (2000
4. Walsh PC, Partin AW, Epstein JI. Cancer control and quality of life following anatomical radical retropubic prostatectomy: Results at 10 years. J. Urol. 152, 1831-1836 (1994
5. Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363, 411-422 (2010
6. Sartor AO. Progression of metastatic castrate-resistant prostate cancer: Impact of therapeutic intervention in the post-docetaxel space. J. Hematol. Oncol. 4, 18 (2011
7. Prostate Cancer: Principles and Practice (1st Edition). Kantoff PW, Carrol PR, D'Amico AV (Eds). Lippincott Williams & Wilkins, Philadelphia, PA, USA (2002
8. Kawalec P, Paszulewicz A, Holko P, Pilc A. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. A systematic review and meta-Analysis. Arch. Med. Sci. 8(5), 767-775 (2012
9. Botrel TE, Clark O, Pompeo AC et al. Immunotherapy with Sipuleucel-T (APC8015) in patients with metastatic castration-refractory prostate cancer (mCRPC): A systematic review and meta-Analysis. Int. Braz. J. Urol. 38(6), 717-727 (2012
10. Small EJ, Higano CS, Kantoff PW, Whitmore JB, Frohlich MW, Petrylak DP. Relationship of sipuleucel-T with time to first use of opioid analgesics (TFOA) in patients (pts) with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC) on the IMPACT trial. J. Clin. Oncol. 31(Suppl. 8), 74 (2013
11. Longo DL. New therapies for castration-resistant prostate cancer. N. Engl. J. Med. 363, 479-481 (2010
12. Peppercorn J, Armstrong A, Zaas DW, George D. Rationing in urologic oncology: Lessons from sipuleucel-T for advanced prostate cancer. Urol. Oncol. 31(7), 1079-1084 (2013
13. Di Lorenzo G, Ferro M, Buonerba C. Sipuleucel-T (Provenge-) for castration-resistant prostate cancer. BJU Int. 110(2 Pt 2), E99-E104 (2012
14. Chambers JD, Neumann PJ. Listening to provenge - What a costly cancer treatment says about future medicare policy. N. Engl. J. Med. 364, 1687-1689 (2011
15. Simoens S. Pharmaco-economic aspects of sipuleucel-T. Hum. Vaccin. Immunother. 8(4), 506-508 (2012
16. Jönsson B, Wilking N. Cancer vaccines and immunotherapeutics: Challenges for pricing, reimbursement and market access. Hum. Vaccin. Immunother. 8(9), 1360-1363 (2012
17. Bahl A, Bellmunt J, Oudard S. Practical aspects of metastatic castration-resistant prostate cancer management: Patient case studies. BJU Int. 109, 14-19 (2012
18. Climent MA, Piulats JM, Sánchez-Hernández A et al. Recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with metastatic castration-resistant prostate cancer. Crit. Rev. Oncol. Hematol. 83, 341-352 (2012
19. Bitting RL, Armstrong AJ, George DJ. Management options in advanced prostate cancer: What is the role for sipuleucel-T. Clin. Med. Insights Oncol. 5, 325-332 (2011
20. Basch EM, Somerfield MR, Beer TM et al. American Society of Clinical Oncology endorsement of the Cancer Care Ontario Practice Guideline on nonhormonal therapy for men with metastatic hormone-refractory (castration-resistant) prostate cancer. J. Clin. Oncol. 25, 5313-5318 (2007
21. Park KT. Perspectives on cost-effective medicine and the use of cost-effectiveness analyses. J. Pediatr. Gastroenterol. Nutr. 54, 2-3 (2012
22. Cost-Effectiveness in Health and Medicine (1st Edition). Gold MR, Siegel JE, Russell LB, Weinstein MC (Eds). Oxford University Press, New York, USA (1996
23. Naimark DMJ, Bott M, Krahn M. The half-cycle correction explained: Two alternative pedagogical approaches. Med. Decis. Making 28, 706-712 (2008
24. Bremner KE, Chong CA, Tomlinson G, Alibhai SM, Krahn MD. A review and meta-Analysis of prostate cancer utilities. Med. Decis. Making 27, 288-298 (2007
25. Alemayehu B, Buysman E, Parry D, Becker L, Nathan F. Economic burden and healthcare utilization associated with castration-resistant prostate cancer in a commercial and Medicare Advantage US patient population. J. Med. Econ. 13, 351-361 (2010
26. Beer TM, Schellhammer PF, Corman JM et al. Quality of life after sipuleucel-T therapy: Results from a randomized, double-blind study in patients with androgen-dependent prostate cancer. Urology 82(2), 410-415 (2013
27. Making Choices in Health: WHO Guide to Cost-Effectiveness Analysis. Tan-Torres Edejer T, Baltussen R, Adam T et al (Eds). World Health Organization, Geneva, Switzerland (2003
28. Schellhammer PF, Chodak G, Whitmore JB, Sims R, Frohlich MW, Kantoff PW. Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trial. Urology 81(6), 1297-1302 (2013
29. Schecter CB. Cost effectiveness in context. J. Clin. Oncol. 25, 609-610 (2007
30. Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 146, 473-481 (1992
31. Gomella L, Nabhan C, DeVries T, Whitmore J, Frohlich M, George D. 683 Estimating the overall survival benefit of sipuleucel-T in the impact trial accounting for crossover treatment in control subjects with autologous immunotherapy generated from cyropreserved cells. J. Urol. 187(4), e278-e279 (2012
32. Huber ML, Haynes L, Parker C, Iversen P. Interdisciplinary Critique of Sipuleucel-T as Immunotherapy in Castration-Resistant Prostate Cancer. J. Natl Cancer Inst. 104(4), 273-279 (2012
33. Collins R, Fenwick E, Trowman R et al. A systematic review and economic model of the clinical effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer. Health Technol. Assess. 11, iii-;iv; xv-xviii; 1-179 (2007
34. Greenberg D, Earle C, Fang CH, Eldar-Lissai A, Neumann PJ. When is cancer care cost-effective? A systematic overview of cost-utility analyses in oncology. J. Natl Cancer Inst. 102(2), 82-88 (2010
35. Kearns B, Lloyd Jones M, Stevenson M, Littlewood C. Cabazitaxel for the second-line treatment of metastatic hormone-refractory prostate cancer: A NICE single technology appraisal. Pharmacoeconomics 31(6), 479-488 (2013
36. Zhong L, Pon V, Srinivas S et al. Therapeutic options in docetaxel-refractory metastatic castration-resistant prostate cancer: A cost-effectiveness analysis. PLoS ONE 8(5), e64275 (2013
37. Seal BS, Asche CV, Puto K, Allen PD. Efficacy, patient-reported outcomes (PROs), and tolerability of the changing therapeutic landscape in patients with metastatic prostate cancer (MPC): A systematic literature review. Value Health 16(5), 872-890 (2013
38. Hao Y, Evans C, Hwang S. PCN105 Recent advances in the treatment of metastatic castration resistant prostate cancer: Impacton health related quality of life. Value Health 16(3), A146-147 (2013